New Immunotherapy Strategy Investigated for Most Common Pediatric Brain Tumor

Sant Joan de Déu Hospital in Barcelona is leading a European consortium evaluating a novel combinatory immunotherapy strategy against DIPG (diffuse intrinsic pontine glioma), one of the most aggressive pediatric brain tumors. The EPICA-DIPG clinical trial aims to test advanced therapeutic approaches to improve outcomes for children with this devastating disease. DIPG accounts for 10-15% of pediatric brain tumors and typically occurs in children ages 5-9 years old. This research represents a significant hope for families facing this life-threatening diagnosis, as current treatment options remain extremely limited.
Originally published on
DiarioSalud.do
By Diario Salud Redacción
Read full article(opens in new tab)Fetched: September 11, 2026 at 10:01 AM



